Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · BDH INDUSTRIES LTD. · 22 September 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
BDH INDUSTRIES LTD.
BSE: 524828
BSE: 524828
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
BDH INDUSTRIES LTD.
StateQ1 FY27 filed
Last close · 20 Sept 2026₹487.90
Market cap₹0.3k cr
TTM P/E · P/B · EV/EBITDA24.0 · 3.65 · 14.6
BDH INDUSTRIES LTD. is a Pharmaceuticals & Biotechnology company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 69 | 74 | 86 | 67 | 96 |
| EBITDA (ex other income) | 10 | 11 | 12 | 12 | 14 |
| margin % | 13.7 | 14.7 | 14.5 | 17.5 | 14.5 |
| Owners' profit | 7 | 8 | 10 | 9 | 11 |
| EPS, as reported (₹) | 12.55 | 14.25 | 17.14 | 16.11 | 18.78 |
| ROE % · ROCE % | 14.9 · 19.8 | 15.0 · 20.3 | 15.9 · 21.4 | 13.5 · 17.9 | 14.0 · 19.3 |
| Debt / equity (x) | 0.05 | 0.09 | 0.14 | 0.01 | 0.03 |
| Cash from operations | 3 | 6 | (2) | 15 | (2) |
| Capex | (0) | (0) | (2) | (0) | (0) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BDH INDUSTRIES LTD. · 22 September 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 16 | 16 | 18 | 19 | 19 | 29 | 29 | 22 |
| Profit before tax | 3 | 4 | 3 | 2 | 4 | 5 | 5 | 4 |
| Net profit | 2 | 3 | 2 | 2 | 3 | 3 | 3 | 3 |
| EPS (₹) | 4.18 | 4.88 | 4.33 | 3.17 | 4.55 | 6.06 | 5.00 | 4.73 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharmaceutical | 29 | 30.1 |
| Renewable Energy | 0 | 0.2 |
| PHARMACEUTICAL | 66 | 69.0 |
| RENEWABLE ENERGY | 1 | 0.7 |
| Total, before eliminations | 96 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,49,869 | 37.2 | 5.36 | 24.1 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,49,683 | 85.5 | 14.90 | 64.4 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,68,282 | 79.4 | 9.57 | 41.6 | 12.2 | 8.0 | 11.8 | 33.1 |
| ZYDUS LIFESCIENCES LTD | 1,16,367 | 26.0 | 3.93 | 15.0 | 17.3 | 18.0 | 12.4 | 25.2 |
| CIPLA LTD | 1,11,403 | 33.0 | 3.23 | 17.1 | 11.2 | 14.7 | 8.0 | 19.7 |
| LAURUS LABS LIMITED | 1,08,995 | 99.6 | 20.07 | 60.7 | 16.4 | 17.2 | 7.2 | 32.0 |
| MANKIND PHARMA LIMITED | 1,00,400 | 49.1 | 6.06 | 27.6 | 11.7 | 10.8 | — | 27.3 |
| DR. REDDY S LABORATORIES | 1,00,367 | 31.1 | 2.63 | 13.5 | 10.9 | 13.0 | 12.1 | 15.0 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 24.0 | 29.6 | 71 of 170 | 58% |
| P/B | 3.6 | 3.3 | 93 of 164 | 44% |
| ROCE | 19.2 | 10.8 | 38 of 183 | 80% |
| ROE | 14.0 | 10.4 | 55 of 171 | 68% |
| Debt / Equity | 0.0 | 0.1 | 60 of 171 | 65% |
| EBITDA margin | 17.5 | 17.5 | 83 of 165 | 50% |
| Revenue growth | 20.2 | 16.3 | 67 of 161 | 59% |
| Profit growth | 49.1 | 30.9 | 65 of 158 | 59% |
| Market cap | 281 | 770 | 108 of 184 | 42% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BDH INDUSTRIES LTD. · 22 September 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 25 Aug 2026 · Notice on special window for physical share dematerialisation | compliance | minimal | — | — |
| 17 Aug 2026 · BDH Industries Q1 FY27 results: profit up 49% YoY | compliance | minimal | — | — |
| 4 Aug 2026 · Board meeting on 14 Aug 2026 to consider Q1 FY27 results | results | low | — | — |
| 22 Jul 2026 · Notice of 36th AGM along with dividend and e-voting details | compliance | minimal | — | — |
| 22 Jul 2026 · BDH Industries fixes 7 Aug 2026 as record date for Rs 5 dividend | corporate actions | medium | — | — |
| 22 Jul 2026 · BDH Industries submits FY26 Annual Report; 36th AGM on 14 August 2026 | board shareholder meetings | medium | — | — |
| 22 Jul 2026 · BDH Industries 36th AGM on 14 Aug 2026, Rs 5 dividend recommended | board shareholder meetings | low | — | — |
| 15 Jul 2026 · Notice to shareholders on transfer of unclaimed shares to IEPF | compliance | minimal | — | — |
| 10 Jul 2026 · BDH Industries 36th AGM notice and shareholder KYC update | compliance | minimal | — | — |
| 10 Jul 2026 · CRISIL reaffirms BBB-/Stable and A3 ratings on Rs 40 Cr bank facilities | credit debt | medium | — | — |
Source: exchange announcements; reaction = close-to-close from the filing's session.
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in